Amdocs (NASDAQ:DOX) Reaches New 12-Month High at $84.17

Shares of Amdocs Limited (NASDAQ:DOXGet Rating) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $84.17 and last traded at $84.14, with a volume of 1993 shares. The stock had previously closed at $83.13.

Separately, upgraded Amdocs from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 24th.

The firm has a market cap of $10.72 billion, a PE ratio of 20.00, a P/E/G ratio of 1.76 and a beta of 0.74. The firm has a 50-day moving average price of $81.03 and a two-hundred day moving average price of $77.37. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.23.

Amdocs (NASDAQ:DOXGet Rating) last announced its quarterly earnings data on Tuesday, February 1st. The technology company reported $1.07 EPS for the quarter, missing the Zacks’ consensus estimate of $1.09 by ($0.02). Amdocs had a return on equity of 15.64% and a net margin of 12.13%. The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter in the previous year, the business posted $1.06 EPS. The business’s quarterly revenue was up 1.7% compared to the same quarter last year. Research analysts forecast that Amdocs Limited will post 4.71 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 29th. Investors of record on Thursday, March 31st will be given a dividend of $0.395 per share. This is an increase from Amdocs’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Wednesday, March 30th. This represents a $1.58 dividend on an annualized basis and a yield of 1.93%. Amdocs’s dividend payout ratio (DPR) is presently 38.63%.

A number of institutional investors have recently made changes to their positions in the stock. Morgan Stanley increased its stake in Amdocs by 2.8% during the third quarter. Morgan Stanley now owns 452,640 shares of the technology company’s stock worth $34,269,000 after acquiring an additional 12,295 shares during the last quarter. Voloridge Investment Management LLC grew its stake in shares of Amdocs by 34.3% in the third quarter. Voloridge Investment Management LLC now owns 169,724 shares of the technology company’s stock valued at $12,850,000 after buying an additional 43,379 shares in the last quarter. GW Henssler & Associates Ltd. acquired a new stake in shares of Amdocs in the fourth quarter valued at $479,000. Richard Bernstein Advisors LLC grew its stake in shares of Amdocs by 6.6% in the third quarter. Richard Bernstein Advisors LLC now owns 38,211 shares of the technology company’s stock valued at $2,892,000 after buying an additional 2,351 shares in the last quarter. Finally, Distillate Capital Partners LLC acquired a new stake in shares of Amdocs in the third quarter valued at $2,731,000. Hedge funds and other institutional investors own 92.99% of the company’s stock.

About Amdocs (NASDAQ:DOX)

Amdocs Limited, through its subsidiaries, provides software and services worldwide. The company designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. It provides CES21, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; the Commerce and Care suite for order capture, handling, and customer engagement; the Monetization suite for charging, billing, policy, and revenue management; Intelligent Networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; MarketONE, a cloud-native business ecosystem; Digital Brands Suite, a pre-integrated digital business suite for digital telecom brands and small-scale service providers; and eSIM Cloud for service providers.

Featured Articles

Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with's FREE daily email newsletter.